The role of magnetic resonance imaging in the diagnosis and management of prostate cancer

BJU International

Volumn 112, Issue SUPPL. 2, 2013, Pages 6-20

  Thompson, James ^a   Lawrentschuk, Nathan ^b   Frydenberg, Mark ^c   Thompson, Les ^d   Stricker, Phillip ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d WESLEY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; CONTRAST MEDIUM; DIAGNOSTIC AGENT;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RISK; CANCER SCREENING; CANCER THERAPY; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLEASON SCORE; HUMAN; IMAGE GUIDED BIOPSY; IMAGING SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REPEAT PROCEDURE; REVIEW; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; STANDARDIZATION; TREATMENT PLANNING; TUMOR VOLUME; BIOPSY; CANCER STAGING; EARLY DIAGNOSIS; EQUIPMENT; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; WATCHFUL WAITING; DEVICES; DIAGNOSTIC USE; PROCEDURES; PROSTATIC NEOPLASMS;

BIOPSY; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; EARLY DETECTION OF CANCER; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; WATCHFUL WAITING;

EID: 84891513700     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12381     Document Type: Review

References (133)

1. Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol 2011; 59: 61-71
2. Barentsz JO, Richenberg J, Clements R et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-57
3. Panel NGR. NCCN Clinical Practice Guidelines in Oncology - Prostate Cancer Treatment. 2012; version 3.0
4. Panel NGR. NCCN Clinical Practice Guidlines in Oncology- Prostate Cancer Early Detection. 2012; Version 2.0
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA-Cancer J Clin 2012; 62: 10-29
6. Schroder FH, Carter HB, Wolters T et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008; 53: 468-77
7. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-90
8. Schroder FH, Van Der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 1817-23
9. Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schroder FH. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 2008; 68: 985-93
10. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001; 166: 104-9; discussion 9-10
11. King CR, McNeal JE, Gill H, Presti JC Jr. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol 2004; 59: 386-91
12. Donohue JF, Bianco FJ Jr, Kuroiwa K et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 2006; 176: 991-5
13. Rifkin MD, Zerhouni EA, Gatsonis CA et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi- institutional cooperative trial.N Engl J Med 1990; 323: 621-6
14. Ahmed HU, Emberton M. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate- specific antigen levels. BJU Int 2009; 104: 269-70; author reply 70
15. Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate- specific antigen levels. BJU Int 2009; 103: 730-3
16. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single- institution experience of 356 patients. Eur J Radiol 2011; 77: 340-5
17. Futterer JJ, Heijmink SW, Scheenen TW et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-58
18. Kim JK, Hong SS, Choi YJ et al. Wash-in rate on the basis of dynamic contrast- enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005; 22: 639-46
19. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25: 146-52
20. Cheikh AB, Girouin N, Colombel M et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 2009; 19: 770-8
21. Chen M, Dang HD, Wang JY et al. Prostate cancer detection: comparison of T2- weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 2008; 49: 602-10
22. Haider MA, Van Der Kwast TH, Tanguay J et al. Combined T2-weighted and diffusion- weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007; 189: 323-8
23. Puech P, Potiron E, Lemaitre L et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009; 74: 1094-9
24. Mazaheri Y, Shukla-Dave A, Hricak H et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging- correlation with pathologic findings. Radiology 2008; 246: 480-8
25. Cruz M, Tsuda K, Narumi Y et al. Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur Radiol 2002; 12: 357-65
26. Ikonen S, Karkkainen P, Kivisaari L et al. Magnetic resonance imaging of clinically localized prostatic cancer. J Urol 1998; 159: 915-9
27. Akin O, Sala E, Moskowitz CS et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006; 239: 784-92
28. Raz O, Haider M, Trachtenberg J, Leibovici D, Lawrentschuk N. MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol 2010; 7: 543-51
29. Ahmed HU, Kirkham A, Arya M et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009; 6: 197-206
30. Kim CK, Park BK, Lee HM, Kwon GY. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 2007; 42: 842-7
31. Morgan VA, Kyriazi S, Ashley SE, Desouza NM. Evaluation of the potential of diffusion- weighted imaging in prostate cancer detection. Acta Radiol 2007; 48: 695-703
32. Engelbrecht MR, Huisman HJ, Laheij RJ et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229: 248-54
33. Barentsz JO, Engelbrecht M, Jager GJ et al. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 1999; 10: 295-304
34. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005; 62: 140-7
35. Beyersdorff DTM, Winkelmann B et al. Patients with a history of elevated prostate- specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002; 224: 701-6
36. Weinreb JC, Blume JD, Coakley FV et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009; 251: 122-33
37. Vargas HA, Akin O, Shukla-Dave A et al. Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology 2012; 265: 478-87
38. Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, Hricak H. Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology 2008; 246: 168-76
39. Ikonen S, Karkkainen P, Kivisaari L et al. Magnetic resonance imaging of prostatic cancer: does detection vary between high and low gleason score tumors? Prostate 2000; 43: 43-8
40. Ellis JH, Tempany C, Sarin MS, Gatsonis C, Rifkin MD, McNeil BJ. MR imaging and sonography of early prostatic cancer: pathologic and imaging features that influence identification and diagnosis. AJR Am J Roentgenol 1994; 162: 865-72
41. Zelhof B, Pickles M, Liney G et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2009; 103: 883-8
42. Morgan VA, Riches SF, Thomas K et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 2011; 84: 31-7
43. Desouza NM, Riches SF, Vanas NJ et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008; 63: 774-82
44. Hambrock T, Somford DM, Huisman HJ et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259: 453-61
45. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF 2nd. Diffusion- weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010; 194: W316-22
46. Turkbey B, Shah VP, Pang Y et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011; 258: 488-95
47. Vargas HA, Akin O, Franiel T et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011; 259: 775-84
48. Zakian KL, Sircar K, Hricak H et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234: 804-14
49. Villeirs GM, Oosterlinck W, Vanherreweghe E, De Meerleer GO. A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. Eur J Radiol 2010; 73: 352-6
50. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, Van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002; 12: 2294-302
51. Park SY, Kim JJ, Kim TH et al. The role of endorectal magnetic resonance imaging in predicting extraprostatic extension and seminal vesicle invasion in clinically localized prostate cancer. Korean J Urol 2010; 51: 308-12
52. Hricak H, White S, Vigneron D et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 1994; 193: 703-9
53. Nakashima J, Tanimoto A, Imai Y et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 2004; 64: 101-5
54. Rorvik J, Halvorsen OJ, Albrektsen G, Ersland L, Daehlin L, Haukaas S. Use of pelvic surface coil MR imaging for assessment of clinically localized prostate cancer with histopathological correlation. Clin Radiol 1999; 54: 164-9
55. Futterer JJ, Engelbrecht MR, Jager GJ et al. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 2007; 17: 1055-65
56. Lee SH, Park KK, Choi KH et al. Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging.World J Urol 2010; 28: 667-72
57. Kim BS, Kim TH, Kwon TG, Yoo ES. Comparison of pelvic phased-array versus endorectal coil magnetic resonance imaging at 3 Tesla for local staging of prostate cancer. Yonsei Med J 2012; 53: 550-6
58. Heijmink SW, Futterer JJ, Hambrock T et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T-comparison of image quality, localization, and staging performance. Radiology 2007; 244: 184-95
59. Abdellaoui A, Iyengar S, Freeman S. Imaging in prostate cancer. Future Oncol 2011; 7: 679-91
60. Afaq A, Koh DM, Padhani A, Van As N, Sohaib SA. Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. BJU Int 2011; 108: 1716-22
61. Lawrence EM, Gnanapragasam VJ, Priest AN, Sala E. The emerging role of diffusion- weighted MRI in prostate cancer management. Nat Rev Urol 2012; 9: 94-101
62. Sciarra A, Barentsz J, Bjartell A et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011; 59: 962-77
63. Hoeks CM, Barentsz JO, Hambrock T et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261: 46-66
64. Riches SF, Payne GS, Morgan VA et al. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. AJR Am J Roentgenol 2009; 193: 1583-91
65. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010; 31:625-31
66. Barrett T, Vargas HA, Akin O, Goldman DA, Hricak H. Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology 2012; 263: 751-7
67. Qayyum A, Coakley FV, Lu Y et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2004; 183: 1079-83
68. Rosenkrantz AB, Kopec M, Kong X et al. Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging.J Magn Reson Imaging 2010; 31: 1387-94
69. Dickinson L, Ahmed HU, Allen C et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59: 477-94
70. Babaian RJ, Toi A, Kamoi K et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163: 152-7
71. Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 2003; 169:125-9
72. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-202; discussion -3
73. Jones JS, Patel A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol 2006; 175: 485-8
74. Jradi MA, Dridi M, Teyeb M et al. The 20-core prostate biopsy as an initial strategy: impact on the detection of prostatic cancer. Can Urol Assoc J 2010; 4: 100-4
75. Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007; 70: 1131-5
76. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate-a 4-year experience. Urology 2007; 70(6 Suppl):27-35
77. Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009; 27: 4321-6
78. Taira AV, Merrick GS, Galbreath RW et al. Performance of transperineal template- guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis 2010; 13: 71-7
79. Stav K, Leibovici D, Sandbank J, Lindner A, Zisman A. Saturation prostate biopsy in high risk patients after multiple previous negative biopsies. Urology 2008; 71: 399-403
80. Moore C, Robertson N, Nasr Arsanious N et al. Image guided prostate biopsy using MR derived targets - a systematic review. Eur Urol 2012; In Press
81. Haffner J, Lemaitre L, Puech P et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011; 108 (8 Pt 2): E171-8
82. Park BK, Park JW, Park SY et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate- specific antigen and no previous biopsy. AJR Am J Roentgenol 2011; 197: W876-81
83. Kasivisvanathan V, Dufour R, Moore CM et al. Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template Prostate Biopsy in the detection of Clinically Significant Prostate Cancer. J Urol 2013; 189: 860-6
84. Hambrock T, Somford DM, Hoeks C et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010; 183: 520-7
85. Hambrock T, Hoeks C, Hulsbergen-Van De Kaa C et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012; 61: 177-84
86. Engehausen DG, Engelhard K, Schwab SA et al. Magnetic resonance image-guided biopsies with a high detection rate of prostate cancer. Scientific World Journal 2012; 2012: 975971
87. Hadaschik BA, Kuru TH, Tulea C et al. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 2011; 186: 2214-20
88. Xu S, Kruecker J, Turkbey B et al. Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg 2008; 13: 255-64
89. Pinto PA, Chung PH, Rastinehad AR et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186: 1281-5
90. Miyagawa T, Ishikawa S, Kimura T et al. Real-time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. Int J Urol 2010; 17: 855-60
91. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12: 897-906
92. Lawrentschuk N, Haider MA, Daljeet N et al. 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int 2010; 105: 1231-6
93. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-7
94. Dong F, Kattan MW, Steyerberg EW et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008; 180: 150-4; discussion 4
95. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005; 23: 8146-51
96. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostatecancer mortality in a randomized European study.N Engl J Med 2009; 360: 1320-8
97. Haas GP, Delongchamps N, Brawley OW, Wang CY, De La Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies.Can J Urol 2008; 15: 3866-71
98. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74
99. Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD. The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer 2008; 112: 971-81
100. Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS. Pathologic Prostate Cancer Characteristics in Patients Eligible for Active Surveillance: A Head-to-Head Comparison of Contemporary Protocols. Eur Urol 2012
101. Vargas HA, Akin O, Afaq A et al. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol 2012; 188: 1732-8
102. Van As NJ, De Souza NM, Riches SF et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2009; 56: 981-7
103. Margel D, Yap SA, Lawrentschuk N et al. Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol 2012; 187: 1247-52
104. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008; 180: 1964-7; discussion 7-8
105. Fradet V, Kurhanewicz J, Cowan JE et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 2010; 256: 176-83
106. Ploussard G, Xylinas E, Durand X et al. Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme. BJU Int 2011; 108: 513-7
107. Cabrera AR, Coakley FV, Westphalen AC et al. Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance? Radiology 2008; 247: 444-50
108. Shukla-Dave A, Hricak H, Kattan MW et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007; 99: 786-93
109. Shukla-Dave A, Hricak H, Akin O et al. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int 2012; 109: 1315-22
110. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997; 202: 697-702
111. Zhang J, Hricak H, Shukla-Dave A et al. Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology 2009; 253: 425-34
112. Bloch BN, Furman-Haran E, Helbich TH et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast- enhanced and T2-weighted MR imaging-initial results. Radiology 2007; 245: 176-85
113. Futterer JJ, Engelbrecht MR, Huisman HJ et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005; 237: 541-9
114. Chandra RV, Heinze S, Dowling R, Shadbolt C, Costello A, Pedersen J. Endorectal magnetic resonance imaging staging of prostate cancer. ANZ J Surg 2007; 77: 860-5
115. Yu KK, Scheidler J, Hricak H et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and threedimensional proton MR spectroscopic imaging. Radiology 1999; 213:481-8
116. Spahn M, Joniau S, Gontero P et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi- institutional study of 712 patients. Eur Urol 2010; 58: 1-7; discussion 10-1
117. Walz J, Joniau S, Chun FK et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2011; 107: 765-70
118. Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 2010; 76: 710-4
119. Briganti A, Joniau S, Gontero P et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 2012; 61: 584-92
120. Pugh TJ, Frank SJ, Achim M et al. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy. Brachytherapy 2012
121. Hricak H, Wang L, Wei DC et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004; 100: 2655-63
122. McClure TD, Margolis DJ, Reiter RE et al. Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy. Radiology 2012; 262: 874-83
123. Kapanen M, Collan J, Beule A, Seppala T, Saarilahti K, Tenhunen M. Commissioning of MRI-only based treatment planning procedure for external beam radiotherapy of prostate. Magn Reson Med 2012
124. Jonsson JH, Brynolfsson P, Garpebring A, Karlsson M, Soderstrom K, Nyholm T. Registration accuracy for MR images of the prostate using a subvolume based registration protocol. Radiat Oncol 2011; 6: 73
125. Jonsson JH, Karlsson MG, Karlsson M, Nyholm T. Treatment planning using MRI data: an analysis of the dose calculation accuracy for different treatment regions. Radiat Oncol 2010; 5: 62
126. Ippolito E, Mantini G, Morganti AG et al. Intensitymodulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity.Am J Clin Oncol 2012; 35: 158-62
127. Riaz N, Afaq A, Akin O et al. Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy. Int J Radiat Oncol, Biol, Phys 2012; 84: 707-11
128. Albert JM, Swanson DA, Pugh TJ et al. Magnetic resonance imaging-based treatment planning for prostate brachytherapy. Brachy 2012
129. Nguyen PL, Chen MH, Zhang Y et al. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol 2012; 188: 1151-6
130. Ahmed HU, Akin O, Coleman JA et al. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 2012; 109: 1636-47
131. Cordeiro ER, Cathelineau X, Thuroff S, Marberger M, Crouzet S, De La Rosette JJ. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU Int 2012
132. Pinthus JH, Farrokhyar F, Hassouna MM et al. Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology. BJU Int 2012
133. Ahmed HU, Hindley RG, Dickinson L et al. Focal therapy for localized unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012; 13: 622-32